John G Ullman & Associates Inc. Has $4.90 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

John G Ullman & Associates Inc. cut its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,750 shares of the specialty pharmaceutical company’s stock after selling 5,344 shares during the quarter. John G Ullman & Associates Inc. owned 0.07% of Jazz Pharmaceuticals worth $4,895,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in JAZZ. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $25,000. UMB Bank n.a. boosted its holdings in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. Itau Unibanco Holding S.A. boosted its holdings in Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 206 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after purchasing an additional 704 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $143.53 on Friday. The company has a fifty day moving average price of $126.69 and a 200-day moving average price of $119.04. The company has a market capitalization of $8.68 billion, a P/E ratio of 20.22, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Analysts Set New Price Targets

A number of research firms have weighed in on JAZZ. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $140.00 to $150.00 in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday. Finally, Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $182.47.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 5,053 shares of company stock valued at $617,442 over the last quarter. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.